Biotech · Public company · Philadelphia, PA, US
Context Therapeutics Inc.
Ticker CNTX · SEC CIK 0001842952
Track this companyFree. Adds Context Therapeutics Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials81 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline4
- ElacestrantPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- OnapristonePhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- CT-95Phase 1 · Mesothelin-Expressing TumorsClinicalTrials.gov · fetched Nov 12, 2026
- CTIM-76Phase 1 · Platinum-resistant Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials8
- CT-95 in Advanced Cancers Associated With Mesothelin ExpressionPHASE1 · TERMINATED · started Mar 31, 2025ClinicalTrials.gov NCT06756035 · fetched Nov 12, 2026
- A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid TumorsPHASE1 · RECRUITING · started Jul 10, 2024ClinicalTrials.gov NCT06515613 · fetched Nov 12, 2026
- A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast CancerPHASE1_PHASE2 · WITHDRAWN · started Jun 1, 2023ClinicalTrials.gov NCT06938711 · fetched Nov 12, 2026
- Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast CancerPHASE1_PHASE2 · TERMINATED · started Dec 2, 2022ClinicalTrials.gov NCT05618613 · fetched Nov 12, 2026
- Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)PHASE2 · TERMINATED · started Oct 5, 2021ClinicalTrials.gov NCT04738292 · fetched Nov 12, 2026
- A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast CancerPHASE1 · WITHDRAWN · started Sep 9, 2021ClinicalTrials.gov NCT04872608 · fetched Nov 12, 2026
- Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial CancerPHASE2 · COMPLETED · started Jan 28, 2021ClinicalTrials.gov NCT04719273 · fetched Nov 12, 2026
- A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to ProgesteronePHASE2 · COMPLETED · started May 2, 2019ClinicalTrials.gov NCT03909152 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Nov 10, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Nov 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 5, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 31, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 26, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 15, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 18, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 1, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 2, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 23, 2026 · fetched Nov 12, 2026